CEREDA, MATTEO
CEREDA, MATTEO
Dipartimento di Oncologia ed Emato-Oncologia
RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade
2024 M. Nokin, A. Mira, E. Patrucco, B. Ricciuti, S. Cousin, I. Soubeyran, S. San José, S. Peirone, L. Caizzi, S. Vietti Michelina, A. Bourdon, X. Wang, D. Alvarez-Villanueva, M. Martínez-Iniesta, A. Vidal, T. Rodrigues, C. García-Macías, M.M. Awad, E. Nadal, A. Villanueva, A. Italiano, M. Cereda, D. Santamaría, C. Ambrogio
Alternative Tissue Fixation Protocols Dramatically Reduce the Impact of DNA Artifacts, Unraveling the Interpretation of Clinical Comprehensive Genomic Profiling
2024 E. Berrino, S.E. Bellomo, A. Chesta, P. Detillo, A. Bragoni, A. Gagliardi, A. Naccarati, M. Cereda, G. Witel, A. Sapino, B. Bussolati, G. Bussolati, C. Marchiò
Sequential treatment with direct KRAS inhibitors: how to improve the management of KRAS G12C drugs
2023 S. Vietti Michelina, P. Scaparone, E. Patrucco, M. Cereda, A. Mira, C. Ambrogio
scGSECA:identification of altered biological processes in single-cell RNA-sequencing data by discretization of expression profiles
2023 S. Perrone, S. Peirone, A. Lauria, F. Priante, M. Caselle, S. Oliviero, M. Cereda
Impaired neutrophil-mediated cell death drives Ewing’s Sarcoma in a two years old child with Down Syndrome
2023 S. Peirone, E. Tirtei, A. Campello, C. Parlato, S. Guarrera, K. Mareschi, E. Marini, S. Dorin Asaftei, L. Bertero, M. Papotti, F. Priante, S. Perrone, M. Cereda, F. Fagioli
Assessing MYC-driven co- and post-transcriptional alterations in prostate cancer with direct RNA long-read sequencing
2023 M. Grieco, S. Peirone, S. Sinha, F. Priante, F. Varese, M. Cereda
Apoptosis in mesenchymal stromal cells activates an immunosuppressive secretome predicting clinical response in Crohn’s disease
2023 T.S. Cheung, C. Giacomini, M. Cereda, A. Avivar-Valderas, D. Capece, G.M. Bertolino, O. Delarosa, R. Hicks, R. Ciccocioppo, G. Franzoso, A. Galleu, F.D. Ciccarelli, F. Dazzi
scGSECA: identification of altered biological processes in single-cell RNA-sequencing data by discretization of expression profiles
2022 S. Perrone, S. Peirone, A. Lauria, M. Caselle, S. Oliviero, M. Cereda
RNAmars: identification of multivalent RNA motifs and cognate regulators of alternative splicing
2022 A. Rissone, M. Del Giudice, S. Peirone, F. Priante, M. Grieco, L. Fumagalli, M. Caselle, U. Pozzoli, M. Cereda
Assessing FOXA1-driven mRNA processing in prostate cancer with Nanopore long-read sequencing
2022 M. Cereda
Molecular characterization of osteosarcoma and Ewing sarcoma in pediatric patients reveals novel RNA-based intervention points
2022 S. Peirone, F. Priante, M. Grieco, M. Del Giudice, E. Tirtei, F. Fagioli, M. Cereda
Molecular characterization of osteosarcoma and Ewing sarcoma in pediatric patients reveals novel RNA-based intervention points
2022 S. Peirone, F. Priante, M. Grieco, E. Tirtei, S. Dorin Asaftei, M. Cereda, F. Fagioli
Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas
2022 E. Berrino, L. Annaratone, S.E. Bellomo, G. Ferrero, A. Gagliardi, A. Bragoni, D. Grassini, S. Guarrera, C. Parlato, L. Casorzo, M. Panero, I. Sarotto, S. Giordano, M. Cereda, F. Montemurro, R. Ponzone, N. Crosetto, A. Naccarati, A. Sapino, C. Marchiò
HNRNPA2B1 controls an unfolded protein response-related prognostic gene signature in prostate cancer
2022 J. G Foster, E. Gea, M. A Labiba, C. A Anene, J. Stockley, C. Philippe, M. Cereda, K. Rouault-Pierre, H. Leung, C. Bessant, P. Rajan
Novel lymphocyte-independent antitumor activity by PD-1 blocking antibody against PD-1+ chemoresistant lung cancer cells
2022 R. Rotolo, V. Leuci, C. Donini, F. Galvagno, A. Massa, M.C. De Santis, S. Peirone, G. Medico, M. Sanlorenzo, I. Vujic, L. Gammaitoni, M. Basiricò, L. Righi, C. Riganti, I.C. Salaroglio, F. Napoli, F. Tabbò, A. Mariniello, E. Vigna, C. Modica, L. D'Ambrosio, G. Grignani, R. Taulli, E. Hirsch, M. Cereda, M. Aglietta, G.V. Scagliotti, S. Novello, P. Bironzo, D. Sangiolo
Collision of germline POLE and PMS2 variants in a young patient treated with immune checkpoint inhibitors
2022 E. Berrino, R. Filippi, C. Visintin, S. Peirone, E. Fenocchio, G. Farinea, F. Veglio, M. Aglietta, A. Sapino, M. Cereda, R. Visintin, B. Pasini, C. Marchi(`(o))
FOXA1 regulates alternative splicing in prostate cancer
2022 M. Del Giudice, J.G. Foster, S. Peirone, A. Rissone, L. Caizzi, F. Gaudino, C. Parlato, F. Anselmi, R. Arkell, S. Guarrera, S. Oliviero, G. Basso, P. Rajan, M. Cereda
Molecular characterization of prostate cancers in the precision medicine era
2021 E.F. Giunta, L. Annaratone, E. Bollito, F. Porpiglia, M. Cereda, G.L. Banna, A. Mosca, C. Marchio, P. Rescigno
Precision medicine in osteosarcoma : MATCH trial and beyond
2021 E. Tirtei, A. Campello, S.D. Asaftei, K. Mareschi, M. Cereda, F. Fagioli
Artificial intelligence in bulk and single-cell rna-sequencing data to foster precision oncology
2021 M.D. Giudice, S. Peirone, S. Perrone, F. Priante, F. Varese, E. Tirtei, F. Fagioli, M. Cereda